InsiderTrades.com logo
World’s biggest multibillionaire investor is buying THIS by the ton [picture]
From Stansberry Research   |   Ad
Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.
Click here to find out what to do.
Carl L. Gordon net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Carl Gordon Biography and Net Worth

Director of Theseus Pharmaceuticals
Carl Lee Gordon founded OrbiMed Advisors LLC.

He is Chairman of Compass Therapeutics, Inc., Principal at Aragon Pharmaceuticals, Inc., Managing Partner at OrbiMed Advisors Private Equity Managing Partner at OrbiMed Advisors LLC which he founded. Dr. Gordon is also on the board of 23 other companies.

Dr. Gordon received a doctorate from Massachusetts Institute of Technology and an undergraduate degree from Harvard College.

What is Carl L. Gordon's net worth?

The estimated net worth of Carl L. Gordon is at least $69.28 million as of July 17th, 2023. Dr. Gordon owns 17,063,000 shares of Theseus Pharmaceuticals stock worth more than $69,275,780 as of April 25th. This net worth approximation does not reflect any other investments that Dr. Gordon may own. Learn More about Carl L. Gordon's net worth.

How do I contact Carl L. Gordon?

The corporate mailing address for Dr. Gordon and other Theseus Pharmaceuticals executives is , , . Theseus Pharmaceuticals can also be reached via phone at 857-400-9491 and via email at [email protected]. Learn More on Carl L. Gordon's contact information.

Has Carl L. Gordon been buying or selling shares of Theseus Pharmaceuticals?

Carl L. Gordon has not been actively trading shares of Theseus Pharmaceuticals in the last ninety days. Most recently, on Monday, July 17th, Carl L. Gordon bought 479,932 shares of Theseus Pharmaceuticals stock. The stock was acquired at an average cost of $3.05 per share, with a total value of $1,463,792.60. Following the completion of the transaction, the director now directly owns 17,063,000 shares of the company's stock, valued at $52,042,150. Learn More on Carl L. Gordon's trading history.

Who are Theseus Pharmaceuticals' active insiders?

Theseus Pharmaceuticals' insider roster includes Timothy Clackson (CEO), Bradford Dahms (CFO), and Carl Gordon (Director). Learn More on Theseus Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Theseus Pharmaceuticals?

In the last twelve months, Theseus Pharmaceuticals insiders bought shares 2 times. They purchased a total of 1,179,932 shares worth more than $3,542,792.60. The most recent insider tranaction occured on July, 17th when Director Carl L Gordon bought 479,932 shares worth more than $1,463,792.60. Insiders at Theseus Pharmaceuticals own 46.7% of the company. Learn More about insider trades at Theseus Pharmaceuticals.

Information on this page was last updated on 7/17/2023.

Carl L. Gordon Insider Trading History at Theseus Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/17/2023Buy479,932$3.05$1,463,792.6017,063,000View SEC Filing Icon  
11/7/2022Buy192,000$5.21$1,000,320.0016,734,518View SEC Filing Icon  
1/21/2022Buy111,896$9.97$1,115,603.12View SEC Filing Icon  
1/19/2022Buy11,521$9.97$114,864.37View SEC Filing Icon  
1/13/2022Buy17,320$9.43$163,327.60View SEC Filing Icon  
1/11/2022Buy8,500$10.51$89,335.00View SEC Filing Icon  
See Full Table

Carl L. Gordon Buying and Selling Activity at Theseus Pharmaceuticals

This chart shows Carl L Gordon's buying and selling at Theseus Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Theseus Pharmaceuticals Company Overview

Theseus Pharmaceuticals logo
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. As of February 14, 2024, Theseus Pharmaceuticals, Inc. operates as a subsidiary of Concentra Biosciences, LLC.
Read More

Today's Range

Now: $4.06
Low: $4.06
High: $4.06

50 Day Range

MA: $4.06
Low: $4.06
High: $4.07

2 Week Range

Now: $4.06
Low: $2.05
High: $12.37

Volume

N/A

Average Volume

592,167 shs

Market Capitalization

$179.57 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.98
World’s biggest multibillionaire investor is buying THIS by the ton [picture]
From Stansberry Research   |   Ad
Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.
Click here to find out what to do.